XML 26 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure
 12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Value of Initial Fixed $100 Investment based on:(3)
Year
Summary Compensation Table Total for First PEO(1)
Compensation Actually Paid to First PEO(1)(2)
Summary Compensation Table Total for Second PEO(1)
Compensation Actually Paid to Second PEO(1)(2)
Average Summary Compensation Table Total for Non-PEO NEOs(1)
Average Compensation Actually Paid to Non-PEO NEOs(1)(2)
Total Shareholder ReturnPeer Group Total Shareholder ReturnNet (Loss) Income (millions)
Adjusted EBITDA %(4)
2024$8,916,147 $4,211,172 $24,236,357 $23,209,027 $2,446,623 $1,902,132 $65.08 $146.87 $(1,118.6)11.8 %
2023$7,059,325 $(1,816,558)$1,675,659 $(222,491)$81.17 $143.18 $(100.2)18.1 %
2022$8,523,732 $(4,535,253)$1,836,308 $(42,128)$113.60 $140.29 $243.1 20.1 %
2021$9,199,748 $28,844,127 $2,474,388 $4,661,522 $152.02 $143.09 $340.5 19.7 %
2020$7,370,894 $14,441,335 $1,640,642 $2,321,660 $113.80 $113.45 $33.3 13.0 %
        
Company Selected Measure Name adjusted EBITDA        
Named Executive Officers, Footnote The First PEO until May 1, 2024 and for 2023, 2022, 2021 and 2020 was Amir Aghdaei. The Second PEO on May 1, 2024 was Paul Keel. The non-PEO NEOs for 2022, 2021 and 2020 were Howard Yu (Senior Vice President and Chief Financial Officer), Jean-Claude Kyrillos (Senior Vice President of Diagnostics and Digital Solutions), Patrik Eriksson (Senior Vice President, President of Nobel Biocare), and Mark Nance (Senior Vice President, General Counsel and Secretary). The non-PEO NEOs for 2023 were Mr. Yu, Mr. Kyrillos, Mr. Eriksson, Mr. Nance, Stephen Keller (Principal Financial Officer) and Eric Conley (Senior Vice President and President, Orthodontics). The non-PEO NEOs for 2024 were Mr. Hammes, Mr. Nance, Mr. Befidi Mr. Reis, and Mr. Keller.        
Peer Group Issuers, Footnote Total shareholder return (“TSR”) is determined based on the value of an initial fixed investment of $100 on December 31, 2019. The Peer Group TSR set forth in this table utilizes the S&P 500 Health Care Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report on Form 10-K for the year ended December 31, 2024. Historical stock performance is not necessarily indicative of future stock performance.        
Adjustment To PEO Compensation, Footnote
Equity award adjustments
YearExecutive(s)SCT TotalDeduct grant date fair value of equity awards reported in SCTAdd year-end value of unvested equity awards granted in yearChange in value of unvested equity awards granted in prior yearsFair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the YearChange in value of equity awards granted in prior years which vested in year
2024First PEO$8,916,147 $(5,500,191)$2,723,931 $(1,018,457)$(910,258)
Second PEO $24,236,357 $(21,400,169)$20,372,839 $(4,218,279)$4,218,279 
Non-PEO NEOs$2,446,623 $(1,399,382)$1,010,312 $(80,640)$(31,917)$(42,863)
2023PEO$7,059,325 $(5,200,178)$1,613,810 $(5,825,994)$536,479 
Non-PEO NEOs$1,675,659 $(971,147)$212,290 $(332,625)$(891,449)$84,781 
2022PEO$8,523,732 $(5,100,321)$2,608,474 $(11,166,139)$599,000 
Non-PEO NEOs$1,836,308 $(1,025,211)$537,397 $(1,446,374)$55,752 
2021PEO$9,199,748 $(4,700,022)$6,694,551 $14,514,792 $3,135,059 
Non-PEO NEOs$2,474,388 $(1,350,182)$2,029,238 $1,321,927 $186,151 
2020PEO$7,370,894 $(4,500,157)$6,904,798 $5,224,388 $(558,588)
Non-PEO NEOs$1,640,642 $(781,373)$1,198,887 $331,885 $(68,381)
        
Non-PEO NEO Average Total Compensation Amount $ 2,446,623 $ 1,675,659 $ 1,836,308 $ 2,474,388 $ 1,640,642
Non-PEO NEO Average Compensation Actually Paid Amount $ 1,902,132 (222,491) (42,128) 4,661,522 2,321,660
Adjustment to Non-PEO NEO Compensation Footnote
Equity award adjustments
YearExecutive(s)SCT TotalDeduct grant date fair value of equity awards reported in SCTAdd year-end value of unvested equity awards granted in yearChange in value of unvested equity awards granted in prior yearsFair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the YearChange in value of equity awards granted in prior years which vested in year
2024First PEO$8,916,147 $(5,500,191)$2,723,931 $(1,018,457)$(910,258)
Second PEO $24,236,357 $(21,400,169)$20,372,839 $(4,218,279)$4,218,279 
Non-PEO NEOs$2,446,623 $(1,399,382)$1,010,312 $(80,640)$(31,917)$(42,863)
2023PEO$7,059,325 $(5,200,178)$1,613,810 $(5,825,994)$536,479 
Non-PEO NEOs$1,675,659 $(971,147)$212,290 $(332,625)$(891,449)$84,781 
2022PEO$8,523,732 $(5,100,321)$2,608,474 $(11,166,139)$599,000 
Non-PEO NEOs$1,836,308 $(1,025,211)$537,397 $(1,446,374)$55,752 
2021PEO$9,199,748 $(4,700,022)$6,694,551 $14,514,792 $3,135,059 
Non-PEO NEOs$2,474,388 $(1,350,182)$2,029,238 $1,321,927 $186,151 
2020PEO$7,370,894 $(4,500,157)$6,904,798 $5,224,388 $(558,588)
Non-PEO NEOs$1,640,642 $(781,373)$1,198,887 $331,885 $(68,381)
        
Compensation Actually Paid vs. Total Shareholder Return
Description of Relationship Between PEO and Other NEO Compensation Actually Paid, Company TSR, and Peer Group TSR

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, the Company’s cumulative TSR over the four most recently completed fiscal years, and the TSR of the S&P 500 Health Care Index over the same period.
tsr.gif
        
Compensation Actually Paid vs. Net Income
Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Net Income

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Net Income during the four most recently completed fiscal years.


netincome.gif
        
Compensation Actually Paid vs. Company Selected Measure
Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Adjusted EBITDA Margin

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our adjusted EBITDA margin during the four most recently completed fiscal years.


ebitda.gif
        
Total Shareholder Return Vs Peer Group
Description of Relationship Between PEO and Other NEO Compensation Actually Paid, Company TSR, and Peer Group TSR

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, the Company’s cumulative TSR over the four most recently completed fiscal years, and the TSR of the S&P 500 Health Care Index over the same period.
tsr.gif
        
Tabular List, Table
•Core Sales Growth
•Free Cash Flow
•Adjusted EBITDA Margin
        
Total Shareholder Return Amount $ 65.08 81.17 113.60 152.02 113.80
Peer Group Total Shareholder Return Amount 146.87 143.18 140.29 143.09 113.45
Net Income (Loss) $ (1,118,600,000) $ (100,200,000) $ 243,100,000 $ 340,500,000 $ 33,300,000
Company Selected Measure Amount 0.118 0.181 0.201 0.197 0.130
Additional 402(v) Disclosure The amounts shown in the Compensation Actually Paid columns have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table (“SCT”) Total with certain adjustments as described below.        
Measure:: 1          
Pay vs Performance Disclosure          
Name Core Sales Growth        
Measure:: 2          
Pay vs Performance Disclosure          
Name Free Cash Flow        
Measure:: 3          
Pay vs Performance Disclosure          
Name Adjusted EBITDA Margin        
Non-GAAP Measure Description We determined adjusted EBITDA margin, calculated consistent with how the Company reports adjusted EBITDA to the public, divided by the Company’s total net sales, to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2024. This performance measure may not have been the most important financial performance measure for years 2021 and 2020, and we may determine a different financial performance measure to be the most important financial performance measure in future years.        
Amir Aghdaei [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount $ 8,916,147 $ 7,059,325 $ 8,523,732 $ 9,199,748 $ 7,370,894
PEO Actually Paid Compensation Amount $ 4,211,172 $ (1,816,558) $ (4,535,253) $ 28,844,127 $ 14,441,335
PEO Name Amir Aghdaei Amir Aghdaei Amir Aghdaei Amir Aghdaei Amir Aghdaei
Paul Keel [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount $ 24,236,357        
PEO Actually Paid Compensation Amount $ 23,209,027        
PEO Name Paul Keel.        
PEO | Amir Aghdaei [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (5,500,191) $ (5,200,178) $ (5,100,321) $ (4,700,022) $ (4,500,157)
PEO | Amir Aghdaei [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,723,931 1,613,810 2,608,474 6,694,551 6,904,798
PEO | Amir Aghdaei [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,018,457) (5,825,994) (11,166,139) 14,514,792 5,224,388
PEO | Amir Aghdaei [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (910,258) 536,479 599,000 3,135,059 (558,588)
PEO | Paul Keel [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (21,400,169)        
PEO | Paul Keel [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 20,372,839        
PEO | Paul Keel [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (4,218,279)        
PEO | Paul Keel [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 4,218,279        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,399,382) (971,147) (1,025,211) (1,350,182) (781,373)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,010,312 212,290 537,397 2,029,238 1,198,887
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (80,640) (332,625) (1,446,374) 1,321,927 331,885
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (42,863) 84,781 $ 55,752 $ 186,151 $ (68,381)
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (31,917) $ (891,449)